Liquidia Technologies (LQDA)
(Delayed Data from NSDQ)
$11.09 USD
+0.05 (0.41%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $11.09 +0.01 (0.05%) 7:58 PM ET
4-Sell of 5 4
F Value D Growth B Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$11.09 USD
+0.05 (0.41%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $11.09 +0.01 (0.05%) 7:58 PM ET
4-Sell of 5 4
F Value D Growth B Momentum F VGM
Zacks News
Wall Street Analysts Believe Liquidia Technologies, Inc. (LQDA) Could Rally 74%: Here's is How to Trade
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 74.1% in Liquidia Technologies, Inc. (LQDA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Liquidia Technologies, Inc. (LQDA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Liquidia Technologies, Inc. (LQDA) delivered earnings and revenue surprises of 37.50% and 11.66%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Cara Therapeutics (CARA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cara (CARA) delivered earnings and revenue surprises of 71.43% and 8.08%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Kiniksa Pharmaceuticals, Ltd. (KNSA) delivered earnings and revenue surprises of 32.56% and 2.56%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Is IQ Chaikin U.S. Small Cap ETF (CSML) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for CSML
Should IQ Chaikin U.S. Small Cap ETF (CSML) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for CSML
United Therapeutics (UTHR) Gains on Tyvaso DPI Approval
by Zacks Equity Research
The FDA approves United Therapeutics' (UTHR) drug-device combination therapy, Tyvaso DPI, for PAH patients. It is a dry-powder inhalation formulation of Treprostinil. Stock gains 8.8%.
Liquidia Technologies, Inc. (LQDA) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Liquidia Technologies, Inc. (LQDA) delivered earnings and revenue surprises of -50% and 7.12%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Aveanna Healthcare (AVAH) Q1 Earnings Lag Estimates
by Zacks Equity Research
Aveanna (AVAH) delivered earnings and revenue surprises of -33.33% and 4.11%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Epizyme (EPZM) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Epizyme (EPZM) delivered earnings and revenue surprises of -11.43% and 19.89%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Insmed (INSM) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Insmed (INSM) delivered earnings and revenue surprises of 12.09% and 0.98%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Liquidia Technologies, Inc. (LQDA) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Liquidia Technologies, Inc. (LQDA) delivered earnings and revenue surprises of -109.09% and 11.13%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Is Liquidia Technologies, Inc. (LQDA) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Liquidia Technologies, Inc. (LQDA) and Assertio (ASRT) have performed compared to their sector so far this year.
Liquidia Technologies, Inc. (LQDA) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Liquidia Technologies, Inc. (LQDA) delivered earnings and revenue surprises of -16.67% and 28.29%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Liquidia Technologies, Inc. (LQDA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Liquidia Technologies, Inc. (LQDA) delivered earnings and revenue surprises of 18.75% and 95.94%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Liquidia Technologies, Inc. (LQDA) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Liquidia Technologies, Inc. (LQDA) delivered earnings and revenue surprises of -5.00% and 260.28%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Rising P/E: An Overlooked Way to Pick 5 Winning Stocks
by Sanghamitra Saha
Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.
Liquidia (LQDA) PAH Drug Gets FDA's Complete Response Letter
by Zacks Equity Research
The CRL issued to the NDA for Liquidia's (LQDA) LIQ861 stated that the FDA cannot approve the NDA in its present form
Zacks.com featured highlights include: Minerva Neurosciences, Liquidia Technologies, Calix, Avenue Therapeutics and ExOne
by Zacks Equity Research
Zacks.com featured highlights include: Minerva Neurosciences, Liquidia Technologies, Calix, Avenue Therapeutics and ExOne
5 Stocks With Recent Price Strength to Tap Wall Street Rally
by Nalak Das
Investors target stocks that are witnessing a bullish run. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.
Why Liquidia Technologies (LQDA) Stock Might be a Great Pick?
by Zacks Equity Research
Liquidia Technologies (LQDA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Liquidia Technologies, Inc. (LQDA) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Liquidia Technologies, Inc. (LQDA) delivered earnings and revenue surprises of -38.46% and -100.00%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Will Liquidia Technologies, Inc. (LQDA) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Liquidia Technologies, Inc. (LQDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Liquidia Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Liquidia.
Liquidia Technologies, Inc. (LQDA) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Liquidia Technologies, Inc. (LQDA) delivered earnings and revenue surprises of -38.46% and -100.00%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?